netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Research Programme in DNA Sequencing

Jul 2, 2014
-
News, RNS Announcements
RNS Number : 1276L
NetScientific PLC
02 July 2014

 

 

 

NetScientific plc

(‘NetScientific’ or the ‘Group’)

Research Programme in DNA Sequencing

 

 

NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with a research institute in the United States.

 

This programme is in a fast-growing, valuable and very competitive field. Notwithstanding the crowded IP landscape, feedback from the US Patent Office on the initial filings is encouraging.

 

 

For further information, please contact

NetScientific plc                                                         

Tel: +44 (0) 20 3590 8877

Farad Azima, Chief Executive Officer

Peter Thoms, Chief Financial Officer

Liberum (Nomad & Broker)                                      

Tel: +44 (0) 20 3100 2222

Chris Bowman / Christopher Britton / Thomas Bective

Bell Pottinger                                                            

Tel: +44 (0) 20 7861 3232

Daniel de Belder

 

 

 

Company website: www.netscientific.net

 

 

ABOUT NETSCIENTIFIC

NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples’ lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCSSSFLFFLSEEW

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Notification of Major Interest In Shares
NEXT POST →
NetScientific plc

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Research Programme in DNA Sequencing - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT